Released on = February 14, 2006, 12:36 am

Press Release Author = La Merie Business Intelligence

Industry = Biotech

Press Release Summary = The TOP 20 blockbuster recombinant proteins and antibodies
achieved record sales of US$ 37.7 bln in the year 2005 while combined sales of the
12 TOP selling classes of recombinant proteins and antibodies reached the US$ 50 bln
threshold.

Press Release Body = Barcelona, Spain | Feb 13, 2006 | The Business Intelligence
firm La Merie S.L. reported today that 19 of the TOP 20 selling biologics achieved
sales of over US$ 1 bln in the year 2005. The strongest growth rates were found for
therapeutic antibodies (Avastin: + 141%; Humira: +64 %; Herceptin: +48 %) which made
out 6 of the 20 biologics. Erythropoietins continue to be the number one selling
class of biological products (excluding vaccines), but with overall modest growth
and conversion from the native protein to the longer-acting glycoengineered. Sales
of the major cancer antibodies (US$ 6.77 bln) came closer to sales of the
TNF-targeting biologics (US$ 7.64 bln). Recombinant insulin-based products are the
number 3 best selling class of biologics. The only antiviral antibody among the TOP
20 biologics achieved for the first time sales of over US$ 1 bln. These results and
more were found in a search conducted by La Merie Business Intelligence published in
the February 13 issue of R&D Pipeline News, edited by La Merie, and can be found at
La Merie's News Center and Online Store PipelineReview.com The document contains
listings of the sales of the TOP 20 blockbuster biologics, of the 12 best selling
classes of biologics and of selected other biologics and is available this week free
as a download at www.pipelinereview.com.

About La Merie

La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high
quality R&D information to the biopharmaceutical industry. La Merie offers
individual consultancy services and publishes reports and periodicals. For more
information visit www.lamerie.com.

About PipelineReview.com

PipelineReview.com is the News Center and Online Store of La Merie Business
Intelligence focused on Research and Development in the Biopharmaceutical Industry.
Visitors of PipelineReview.com will find R&D relevant press releases and can receive
selected R&D news from one or more of the site's News Channels. A free R&D Newletter
conveniently brings via e-mail a daily selection of the most intersting news from
biopharmaceutical R&D. For more information visit www.pipelinereview.com.

About R&D Pipeline News

R&D Pipeline News is a premier information source about research and development
projects in the pipeline of the biopharmaceutical industry and is directed to all
stakeholders in R&D. The weekly publication comes in a rapid- and easy-to-screen
tabular format and provides access to the original information source via
hyperlinks. R&D Pipeline News covers all relevant treatment modalities and is
directly delivered to the desktop via e-mail. More information about the journal, a
free trial and subscriptions are available via La Merie's Business Intelligence
Center www.pipelinereview.com.

Web Site = http://www.lameri.com/newsroom

Contact Details = Jorge Márquez
La Merie Business Intelligence
C/ Caspe, 33B, 4º, 2ª
E-08010 Barcelona
Tel +34-93-342 91 97
Fax +34-93-342 91 98
e-mail: jorge.marquez@lamerie.com
Website: http://www.lamerie.com
Online Store: www.pipelinereview.com